German Pharma Balks As Second HTA Retrospective Assessment Includes Orphan Drugs
This article was originally published in The Pink Sheet Daily
Germany’s senior reimbursement body, the G-BA, has announced it will assess a second wave of older drugs, despite a pending coalition agreement dropping this practice.
You may also be interested in...
German Drug Price Freeze Confirmed For Four Years In Latest Reforms
Germany’s pharmaceutical sector reforms represent a mixed bag for industry, with the price freeze set to continue, while rebate levels to health insurers are slashed.
German Pharma Wants Inflation-Linked Deal To Replace Drug Price Freeze
With the German drug price freeze set to continue, the pharmaceutical industry wants to see at least an inflation-linked rise in prices and the abandonment of HTA for older products.
Germany’s Grand Coalition Offers Pharma Little Certainty, Except For Continued Discounts
Germany’s new grand coalition government includes a health minister with no background in health care.